



LTKfarma



President Evence-Charles COPPEE

Scientific founders David KLATZMANN François LEMOINE José COHEN

Contact details Pépinière Genopole® Entreprises - 4, rue Pierre Fontaine - F-91000 EVRY

Tel +33 6 08 97 78 51

E-mail LTKfarma@neuf.fr

Date of founding March 2006

BUSINESS SECTOR

- Biopharmaceuticals/Healthcare

FIELD OF ACTIVITY

- **Discovery, development and marketing of cell therapy products (derived from modified T-cells) for the treatment of leukemia and autoimmune diseases**

DESCRIPTION

▪ **LTKfarma** is a research-driven, early-stage biopharmaceutical company developing a genetic immunosuppression strategy for the application of scientific discoveries pioneered by the founding scientists: Professors David Klatzmann and François Lemoine and Dr José Cohen (CNRS/UPMC ESA 7087 Biology and Therapy of Immune Diseases Unit and the Biotherapy Service, Pierre and Marie Curie University, Pitié-Salpêtrière Hospital, Paris, France).

LTKfarma's main objectives are to:

1. Drastically reduce mortality from graft-versus-host disease (GVHD), the main complication of allogeneic, hematopoietic stem cell transplantation (HSCT), i.e. a target figure of 5% instead of today's 20%-60%.
2. Offer a new therapeutic solution that overcomes graft shortages in HSCT for leukemia patients.

3. Offer HSCT as a therapeutic alternative with an enhanced risk/benefit ratio for patients suffering from severe forms of autoimmune diseases such as scleroderma, multiple sclerosis and rheumatoid arthritis.

The company is currently seeking industrial and commercial partnerships for the development and commercialization of its TK54 product. LTKFarma is equally looking for fundraising opportunities in order to initiate pivotal clinical studies with the objective of a first NDA before 2011.